Current Headlines

  1. Viva Biotech Launches The AI-Driven Drug Discovery Platform, Transforming New Drug R&D Logic, Enabling One-Stop Innovative Drug Discovery 5/15/2025

    On May 13, 2025, Viva Biotech successfully held the AIDD platform launch event "Enchantment of Drug Discovery," unveiling the advanced and comprehensive AI-Driven Drug Discovery (AIDD) platform.

  2. Clarivate Enhances OFF-X With Pathway Maps To Accelerate Target Safety Assessments 5/14/2025

    Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, today announced the incorporation of Pathway Maps in OFF-X, a cutting-edge translational safety intelligence solution.

  3. AbTherx, Single Cell Technology, And Vaccinex Announce Collaboration To Tackle Challenging Antibody Drug Targets 5/13/2025

    AbTherx, Inc., a biotechnology company with innovative transgenic technologies that simplify and accelerate antibody discovery, today announced a collaboration with Single Cell Technology and Vaccinex. AbTherx and Single Cell Technology will incorporate Vaccinex's ActivMAb Technology into their respective workflows for complex drug targets.

  4. Comend And Odylia Partner To Advance Rare Disease Drug Development With Innovative Patient-Driven Platform 5/13/2025

    Comend, a software company building solutions for Patient Advocacy Groups (PAGs), and Odylia Therapeutics, a nonprofit drug development organization dedicated to advancing treatments for rare diseases, are excited to announce a strategic partnership aimed at transforming the rare disease research ecosystem.

  5. CytoTronics Expands Pixel Capability With Multi-Modal Cardiac Application For Early Screening Of Drug Candidates In Cardiovascular Research 5/13/2025

    CytoTronics, Inc., a pioneer of semiconductor-based platforms for discovery in cell biology, launched their novel Cardiac application today—the next key offering in its Pixel application portfolio.

  6. AI Tool Predicts Potential Drug Targets By Analyzing Cell Images 5/13/2025

    A new AI model developed by researchers at the Eric and Wendy Schmidt Center at the Broad Institute and ETH Zurich’s Department of Health Science and Technology can identify genes that have been altered, such as ones that might be causing a disease, in a cell just by analyzing an image of the cell’s chromatin — the dense package of chromosomes inside the cell’s nucleus.

  7. Thermosome Receives U.S. Orphan Drug Designation For Lead Compound THE001, Expands Patent Estate 5/12/2025

    Thermosome, a drug development company focused on targeted tumor therapies, today announced that its lead compound, THE001, has been granted Orphan Drug Designation (ODD) by the U.S. Food and Drug Administration (FDA) for the treatment of soft tissue sarcomas (STS).

  8. NanoTemper Announces Prometheus Panta C: Powering Biopharma Breakthroughs From Preclinical To Commercial Manufacturing 5/12/2025

    NanoTemper Technologies today introduces Prometheus Panta C, a system built to power biopharma breakthroughs by delivering high-quality protein stability and aggregation data.

  9. Lantern Pharma Secures FDA Clearance For Planned Phase 1b/2 Trial Of LP-184 In Biomarker-Defined, Treatment-Resistant NSCLC Patients With High Unmet Clinical Need 5/12/2025

    Lantern Pharma Inc., an artificial intelligence company developing targeted and transformative cancer therapies using its proprietary AI platform, RADR, today announced that the U.S. Food and Drug Administration (FDA) has cleared the amendment to its Investigational New Drug (IND) application to initiate a Phase 1b/2 clinical trial of LP-184 in a genomically defined patient population of non-small cell lung cancer (NSCLC) where there is a need to improve patient outcomes.

  10. Cell Death Discovery Could Lead To Next-Gen Drugs For Neurodegenerative Conditions 5/12/2025

    Researchers have discovered how to block cells dying, in a finding that could lead to new treatments for neurodegenerative conditions like Parkinson’s and Alzheimer’s.